New EU contraindication and warnings for Novartis's aliskiren
This article was originally published in Scrip
The CHMP wants changes to the labels of products containing Novartis's troubled anithypertensive aliskiren that will massively curtail its recommended patient population, but it has stopped short of recommending the drug's removal from the market.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.